In the last few years, various monoclonal antibody therapies have been developed with anti-TNF-α targets such as infliximab, adalimumab or etanercept, used in the treatment of rheumatoid arthritis, Crohn’s disease, ankylosing spondylitis, psoriasis and other inflammatory diseases, despite the risk of related side effects [15]. The gene discussed is TNF; the disease is psoriasis.